Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 391

1.

Characterizing genomic differences of human cancer stratified by the TP53 mutation status.

Wang M, Yang C, Zhang X, Li X.

Mol Genet Genomics. 2018 Jun;293(3):737-746. doi: 10.1007/s00438-018-1416-7. Epub 2018 Jan 12.

PMID:
29330617
2.

Integrative genomic and transcriptomic analysis of leiomyosarcoma.

Chudasama P, Mughal SS, Sanders MA, Hübschmann D, Chung I, Deeg KI, Wong SH, Rabe S, Hlevnjak M, Zapatka M, Ernst A, Kleinheinz K, Schlesner M, Sieverling L, Klink B, Schröck E, Hoogenboezem RM, Kasper B, Heilig CE, Egerer G, Wolf S, von Kalle C, Eils R, Stenzinger A, Weichert W, Glimm H, Gröschel S, Kopp HG, Omlor G, Lehner B, Bauer S, Schimmack S, Ulrich A, Mechtersheimer G, Rippe K, Brors B, Hutter B, Renner M, Hohenberger P, Scholl C, Fröhling S.

Nat Commun. 2018 Jan 10;9(1):144. doi: 10.1038/s41467-017-02602-0.

3.

A case report of adult cerebellar high-grade glioma with H3.1 K27M mutation: a rare example of an H3 K27M mutant cerebellar tumor.

Funata N, Nobusawa S, Nakata S, Yamazaki T, Takabagake K, Koike T, Maegawa T, Yamada R, Shinoura N, Mine Y.

Brain Tumor Pathol. 2018 Jan;35(1):29-35. doi: 10.1007/s10014-017-0305-9. Epub 2017 Dec 20.

PMID:
29264735
4.

H3.3K27M Cooperates with Trp53 Loss and PDGFRA Gain in Mouse Embryonic Neural Progenitor Cells to Induce Invasive High-Grade Gliomas.

Pathania M, De Jay N, Maestro N, Harutyunyan AS, Nitarska J, Pahlavan P, Henderson S, Mikael LG, Richard-Londt A, Zhang Y, Costa JR, Hébert S, Khazaei S, Ibrahim NS, Herrero J, Riccio A, Albrecht S, Ketteler R, Brandner S, Kleinman CL, Jabado N, Salomoni P.

Cancer Cell. 2017 Nov 13;32(5):684-700.e9. doi: 10.1016/j.ccell.2017.09.014. Epub 2017 Oct 26.

PMID:
29107533
5.

Extrachromosomal telomere repeat DNA is linked to ALT development via cGAS-STING DNA sensing pathway.

Chen YA, Shen YL, Hsia HY, Tiang YP, Sung TL, Chen LY.

Nat Struct Mol Biol. 2017 Dec;24(12):1124-1131. doi: 10.1038/nsmb.3498. Epub 2017 Nov 6.

PMID:
29106411
6.

Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas.

Cancer Genome Atlas Research Network. Electronic address: elizabeth.demicco@sinaihealthsystem.ca; Cancer Genome Atlas Research Network.

Cell. 2017 Nov 2;171(4):950-965.e28. doi: 10.1016/j.cell.2017.10.014.

7.

Identification of Clinical and Biologic Correlates Associated With Outcome in Children With Adrenocortical Tumors Without Germline TP53 Mutations: A St Jude Adrenocortical Tumor Registry and Children's Oncology Group Study.

Pinto EM, Rodriguez-Galindo C, Pounds SB, Wang L, Clay MR, Neale G, Garfinkle EAR, Lam CG, Levy CF, Pappo AS, Zambetti GP, Ribeiro RC.

J Clin Oncol. 2017 Dec 10;35(35):3956-3963. doi: 10.1200/JCO.2017.74.2460. Epub 2017 Oct 23.

PMID:
29058986
8.

Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications.

Miller JJ, Shih HA, Andronesi OC, Cahill DP.

Cancer. 2017 Dec 1;123(23):4535-4546. doi: 10.1002/cncr.31039. Epub 2017 Oct 5. Review.

PMID:
28980701
9.

Structural basis for DAXX interaction with ATRX.

Wang X, Zhao Y, Zhang J, Chen Y.

Protein Cell. 2017 Oct;8(10):767-771. doi: 10.1007/s13238-017-0462-y. No abstract available.

10.

Structural and biochemical characterization of DAXX-ATRX interaction.

Li Z, Zhao D, Xiang B, Li H.

Protein Cell. 2017 Oct;8(10):762-766. doi: 10.1007/s13238-017-0463-x. No abstract available.

11.

IDH1 status is significantly different between high-grade thalamic and superficial gliomas.

Zuo M, Li M, Chen N, Yu T, Kong B, Liang R, Wang X, Mao Q, Liu Y.

Cancer Biomark. 2017 Aug 23;20(2):183-189. doi: 10.3233/CBM-170175.

PMID:
28869450
12.

ATRX is a regulator of therapy induced senescence in human cells.

Kovatcheva M, Liao W, Klein ME, Robine N, Geiger H, Crago AM, Dickson MA, Tap WD, Singer S, Koff A.

Nat Commun. 2017 Aug 30;8(1):386. doi: 10.1038/s41467-017-00540-5.

13.

The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas.

Lee Y, Koh J, Kim SI, Won JK, Park CK, Choi SH, Park SH.

Acta Neuropathol Commun. 2017 Aug 29;5(1):62. doi: 10.1186/s40478-017-0465-1.

14.

Modified rapid immunohistochemical staining for intraoperative diagnosis of malignant brain tumors.

Suzuki A, Maruyama T, Nitta M, Komori T, Ikuta S, Kawamata T, Muragaki Y.

Brain Tumor Pathol. 2017 Oct;34(4):141-148. doi: 10.1007/s10014-017-0293-9. Epub 2017 Aug 19.

PMID:
28823098
15.

Diagnostic implications of TERT promoter mutation status in diffuse gliomas in a routine clinical setting.

Hewer E, Prebil N, Berezowska S, Gutt-Will M, Schucht P, Dettmer MS, Vassella E.

Virchows Arch. 2017 Nov;471(5):641-649. doi: 10.1007/s00428-017-2216-x. Epub 2017 Aug 19.

PMID:
28823044
16.

A simple algorithmic approach using histology and immunohistochemistry for the current classification of adult diffuse glioma in a resource-limited set-up.

Rajeswarie RT, Rao S, Nandeesh BN, Yasha TC, Santosh V.

J Clin Pathol. 2018 Apr;71(4):323-329. doi: 10.1136/jclinpath-2017-204638. Epub 2017 Aug 11.

PMID:
28801347
17.

Radiation-induced gliomas: a report of four cases and analysis of molecular biomarkers.

Nakao T, Sasagawa Y, Nobusawa S, Takabatake Y, Sabit H, Kinoshita M, Miyashita K, Hayashi Y, Yokoo H, Nakada M.

Brain Tumor Pathol. 2017 Oct;34(4):149-154. doi: 10.1007/s10014-017-0292-x. Epub 2017 Aug 9.

PMID:
28795231
18.

Repression of Stress-Induced LINE-1 Expression Protects Cancer Cell Subpopulations from Lethal Drug Exposure.

Guler GD, Tindell CA, Pitti R, Wilson C, Nichols K, KaiWai Cheung T, Kim HJ, Wongchenko M, Yan Y, Haley B, Cuellar T, Webster J, Alag N, Hegde G, Jackson E, Nance TL, Giresi PG, Chen KB, Liu J, Jhunjhunwala S, Settleman J, Stephan JP, Arnott D, Classon M.

Cancer Cell. 2017 Aug 14;32(2):221-237.e13. doi: 10.1016/j.ccell.2017.07.002. Epub 2017 Aug 3.

PMID:
28781121
19.

Serotonin, ATRX, and DAXX Expression in Pituitary Adenomas: Markers in the Differential Diagnosis of Neuroendocrine Tumors of the Sellar Region.

Casar-Borota O, Botling J, Granberg D, Stigare J, Wikström J, Boldt HB, Kristensen BW, Pontén F, Trouillas J.

Am J Surg Pathol. 2017 Sep;41(9):1238-1246. doi: 10.1097/PAS.0000000000000908.

PMID:
28719461
20.

miR-380-5p-mediated repression of TEP1 and TSPYL5 interferes with telomerase activity and favours the emergence of an "ALT-like" phenotype in diffuse malignant peritoneal mesothelioma cells.

Cimino-Reale G, Gandellini P, Santambrogio F, Recagni M, Zaffaroni N, Folini M.

J Hematol Oncol. 2017 Jul 17;10(1):140. doi: 10.1186/s13045-017-0510-3.

Supplemental Content

Loading ...
Support Center